CN212140660U - Degradable lacrimal duct tube - Google Patents

Abstract

The utility model provides a degradable lacrimal passage pipe, fastener and the medicine coating of making including pipeline, degradable material that degradable material made, be provided with one or more through-holes in the pipeline week, the fastener is cambered surface shape and/or disc, and the coaxial setting of one or more fastener is at the tip or the middle part of pipeline, and the size of fastener is greater than the size of pipeline, coats the medicine coating on the internal surface of pipeline and/or the surface. The utility model has simple structure, convenient and fast implantation, is not easy to fall off after implantation, can be degraded and disappear after a period of time, and does not need to be taken out, thereby avoiding the damage to the affected part when being taken out, reducing the complications left after the taking out and reducing the pain of patients; the utility model can realize the antibacterial and anti-inflammatory effects and promote the healing of the affected part by the slow release of the drug coating on the pipeline; the utility model discloses can be applicable to the disease of multiple difference, application scope is extensive.

Description

Degradable lacrimal duct tube

Technical Field

The utility model relates to the technical field of medical equipment, specifically, relate to a degradable lacrimal passage pipe.

Background

The lacrimal passage is the conduit between the inner canthus and the nasal cavity: from top to bottom, it is composed of punctum, lacrimal canaliculus, common lacrimal duct, lacrimal sac and nasolacrimal duct, and its function is to drain tears. If the lacrimal passage is blocked and the drainage of lacrimal fluid is blocked due to stenosis, inflammation, trauma, etc., the lacrimal sac is easy to grow bacteria due to the accumulation of lacrimal fluid, which causes lacrimal passage diseases.

At present, lacrimal duct catheters are usually installed to treat lacrimal duct diseases, but the defects that the catheters are easy to block and cannot conduct drainage, the surfaces of the catheters are smooth and difficult to fix and are easy to fall off, hollow catheters are easy to be pressed and deformed and the like generally exist, the lacrimal duct catheters need to be taken out again after recovery, particularly, the lacrimal duct catheters are adhered to lacrimal duct mucous membranes and are difficult to take out, 70 percent of the catheters are broken, granulation and scars are caused, the curative effect is low, and the clinical application of intubation is greatly limited.

Patent document CN 202151387U discloses a lacrimal duct stent, which includes: a hollow silicone tube, one end of which is in a closed spherical shape; the silica gel strip is in a solid strip shape and is connected to the other end of the silica gel tube; and the guide needle can penetrate into the hollow part in the silicone tube. The silicone tube is provided with at least one small hole for penetrating the silicone tube. The materials adopted by the scheme are not degradable, need to be taken out again after recovery, are difficult to fix after being implanted and are easy to fall off, and once the silicone tube is adhered to the mucosa, the silicone tube is difficult to take and is easy to break.

SUMMERY OF THE UTILITY MODEL

To the defects in the prior art, the utility model aims at providing a degradable lacrimal duct tube.

According to the utility model provides a pair of degradable lacrimal passage pipe, fastener and the medicine coating of making including pipeline, degradable material that degradable material made, be provided with one or more through-holes in the pipeline week, the fastener is cambered surface shape and/or disc, and the coaxial setting of one or more fastener is at the tip or the middle part of pipeline, and the size of fastener is greater than the size of pipeline, coats the medicine coating on the internal surface of pipeline and/or the surface.

Preferably, the joint of the clamping piece and the pipeline is hollow and is communicated with the pipeline.

Preferably, the joint of the clamping piece and the pipeline is solid and seals the pipeline.

Preferably, the cambered surface-shaped clamping piece comprises a top surface cambered surface and a bottom surface, the top surface cambered surface is connected with the bottom surface, and the bottom surface is a plane or a cambered surface with the radius larger than that of the top surface cambered surface.

Preferably, the pipe is a flexible pipe capable of bending.

Preferably, the conduit comprises a plurality of lengths of coaxially connected pipe bodies of different internal and/or external diameters.

Preferably, the inner and/or outer diameter of the pipe remains constant in the direction of extension of the pipe.

Preferably, the conduit is integrally formed with the clip.

Preferably, the through holes on the circumferential direction of the pipeline are distributed in a staggered mode, and the diameter of each through hole is smaller than the outer diameter of the pipeline.

The utility model provides a degradable lacrimal passage tube, including pipeline, the fastener and the medicine coating that the degradable material made of degradable material, the pipeline circumference is provided with one or more through-holes, the fastener is cambered surface shape and/or disc, one or more fasteners coaxial setting is in the tip or the middle part of pipeline, the size of fastener is greater than the size of pipeline, coat the medicine coating on the internal surface and/or the surface of pipeline;

the connecting part of the clamping piece and the pipeline is hollow and is communicated with the pipeline;

the joint of the clamping piece and the pipeline is solid and plugs the pipeline;

the cambered surface-shaped clamping piece comprises a top surface cambered surface and a bottom surface, the top surface cambered surface is connected with the bottom surface, and the bottom surface is a plane or a cambered surface of which the radius is larger than that of the top surface cambered surface;

the pipeline is a flexible pipeline capable of being bent;

the pipeline comprises a plurality of sections of coaxially connected pipe bodies with different inner diameters and/or outer diameters;

the inner diameter and/or the outer diameter of the pipeline are/is kept unchanged in the extending direction of the pipeline;

the pipeline and the clamping piece are integrally formed;

the through holes in the circumferential direction of the pipeline are distributed in a staggered mode, and the diameter of each through hole is smaller than the outer diameter of the pipeline.

Compared with the prior art, the utility model discloses following beneficial effect has:

1. the utility model discloses simple structure implants convenient and fast, is difficult for droing after implanting, and can degrade after a period and disappear, need not to take out to the injury in affected part when avoiding taking out reduces the back and loses complication, reduces patient's misery.

2. The utility model discloses a drug coating on the pipeline slowly releases, can antibiotic anti-inflammatory, promotes the cure in affected part.

3. The utility model discloses can be applicable to the disease of multiple difference, application scope is extensive.

Drawings

Other features, objects and advantages of the invention will become more apparent upon reading of the detailed description of non-limiting embodiments with reference to the following drawings:

fig. 1 is a schematic structural diagram of a first embodiment of the present invention.

Fig. 2 is a schematic structural diagram of a second embodiment of the present invention.

Fig. 3 is a schematic structural diagram of a third embodiment of the present invention.

Fig. 4 is a schematic structural diagram of a fourth embodiment of the present invention.

Fig. 5 is a schematic structural diagram of the auxiliary pre-device.

Fig. 6 is a schematic structural view of the auxiliary forceps.

Fig. 7 is a schematic structural view of an auxiliary lacrimal passage retractor hook.

Fig. 8 is a schematic structural view of the auxiliary hollow probe.

Fig. 9 is a schematic view of the lacrimal system.

The figures show that:

auxiliary guide wire member 18 of first arc-shaped clamping member 1

The drug coating 2 assists the olive 19

Disc-shaped clamping piece 3 auxiliary wire guiding piece 21

Clamping tip 26 of pipeline 4

Through hole 5 handhold part 27

Straight lever handle 28 of second arc-shaped clamping piece 6

Third arc fastener 7 towing hook 29

Preset lacrimal passage tube 11 probe handle 30

Hand-held placing device 12 hollow tube needle 31

Punctal dilation device 13

Detailed Description

The present invention will be described in detail with reference to the following embodiments. The following examples will assist those skilled in the art in further understanding the present invention, but are not intended to limit the invention in any way. It should be noted that various changes and modifications can be made by one skilled in the art without departing from the spirit of the invention. These all belong to the protection scope of the present invention.

In the description of the present application, it is to be understood that the terms "upper", "lower", "front", "rear", "left", "right", "vertical", "horizontal", "top", "bottom", "inner", "outer", and the like indicate orientations or positional relationships based on those shown in the drawings, and are only for convenience in describing the present application and simplifying the description, but do not indicate or imply that the referred device or element must have a specific orientation, be constructed in a specific orientation, and be operated, and thus, should not be construed as limiting the present application.

According to the utility model provides a pair of degradable lacrimal passage pipe, as shown in fig. 1-4, pipeline, the fastener and the medicine coating that degradable material made including degradable material made, the pipeline is provided with one or more through-holes in the week, the fastener is cambered surface shape and/or disc, and the coaxial setting of one or more fastener is at the tip or the middle part of pipeline, and the size of fastener is greater than the size of pipeline, coats the medicine coating on the internal surface of pipeline and/or the surface. Preferably, the through holes on the pipe are micropores.

The connecting part of the clamping piece and the pipeline is hollow and is communicated with the pipeline. Or the joint of the clamping piece and the pipeline is solid and plugs the pipeline. The cambered surface-shaped clamping piece comprises a top surface cambered surface and a bottom surface, the top surface cambered surface is connected with the bottom surface, and the bottom surface is a plane or a cambered surface with the radius larger than that of the top surface cambered surface.

The pipeline is a flexible pipeline capable of being bent. The pipe comprises a plurality of sections of coaxially connected pipes of different inner and/or outer diameters. Or the inner and/or outer diameter of the pipe may be kept constant in the direction of extension of the pipe. The pipeline and the clamping piece are integrally formed. The through holes in the circumferential direction of the pipeline are distributed in a staggered mode, and the diameter of each through hole is smaller than the outer diameter of the pipeline.

Example 1:

as shown in fig. 1, a lacrimal passage tube comprises a first arc-shaped clamping piece 1, a drug coating 2, a disc-shaped clamping piece 3, a pipeline 4 and a through hole 5, wherein the first arc-shaped clamping piece 1 and the disc-shaped clamping piece 3 are respectively arranged at two ends of the pipeline 4, the joints of the first arc-shaped clamping piece 1, the disc-shaped clamping piece 3 and the pipeline 4 are all hollow and communicated with the pipeline 4, the first arc-shaped clamping piece 1 comprises a top surface arc surface and a bottom surface plane, and the top surface arc surface faces outwards; the lacrimal duct is implanted into the affected part through the auxiliary pre-device shown in fig. 5; the auxiliary preassembly includes the pre-placement lacrimal tubing 11, the hand-held placement device 12, and the punctum dilation device 13. The top end of a preset lacrimal duct pipe fitting 11 is placed in advance in a pipeline 4 of a lacrimal duct pipe, a hand-held placing device 12 is held by hands, a lacrimal point expanding device 13 is used for probing into the position of a lacrimal point and expanding and dredging, then a first arc-shaped clamping piece 1 at the end part of the pipeline is firstly sent into the lacrimal point, the front end part of the lacrimal duct pipe is slowly placed in the pipeline 4, a disc-shaped clamping piece 3 is kept at the lacrimal point outside the lacrimal duct pipe and stays at an eyelid, then the preset lacrimal duct pipe fitting 11 is drawn out, a central hole and a circumferential through hole 5 of the pipeline 4 can allow lacrimal fluid to flow out through the hole, so that the lacrimal duct pipe has the function of controlling lacrimal fluid excretion and the function of supporting, a drug coating 2 on the pipeline 4 is slowly released, the functions of resisting bacteria and diminishing inflammation are achieved, the lacrimal duct pipe is made of degradable materials, and the.

Through adopting the lacrimal passage tube structure shown in fig. 1, practically solved the lacrimal punctum local block collapse of patient and the lacrimal punctum full surface that the stenosis arouses, the lacrimal passage tube keeps the lacrimal punctum opening to expand for several weeks time as supporting expansion lacrimal punctum structure, make tear smoothly discharge through lacrimal passage tube micropore and central hole pipe, simultaneously because of there is medicine or biological dressing of medicine coating 2 on the pipeline 4 to directly act on in inflammation department slow release, play the anti-inflammatory action, avoid infecting the inflammatory response, the automatic degradation of lacrimal passage tube structure after several weeks, need not to take out, the cure rate is showing and improves, greatly reduce the economic cost and the time cost of patient and hospital, the drawback limitation of product technology before having solved: because the catheter is not degradable, the patient can get the catheter in the hospital for a plurality of times, the catheter taking difficulty is increased due to long time, the catheter is easy to break, the cost of the patient is increased, and the time of a doctor is consumed; and the curative effect is not obvious, the application range is narrow, the disease condition is repeated, and complications occur after birth: granulation, scar hyperplasia, inflammatory reaction; the disease is generally from most common people in the primary rural area, the labor and the life quality of the people are seriously influenced, and the automatic degradation of the lacrimal duct tube structure is revolutionary breakthrough innovation.

Another use of lacrimal canaliculi is: through adopting the lacrimal passage tubular construction shown in fig. 1, solve the local shutting of the urethra of old patient's urinary system and subside, the stenosis arouses the micturition difficulty, it keeps urethra opening to expand for a few weeks time to use lacrimal passage pipe as supporting expansion urethra structure, make the urine smoothly discharge through the circular portion of centre bore, medicine or biological dressing in the medicine coating 2 on the pipeline 4, play the anti-inflammatory effect, avoid infecting inflammatory response, porose tear tubule structure automatic degradation after a few weeks, need not to get away, the cure rate is showing and is improving.

Example 2:

as shown in fig. 2, a lacrimal passage tube comprises a second arc-shaped clamping piece 6, a medicine coating 2, a disc-shaped clamping piece 3, a pipeline 4 and a through hole 5, wherein the second arc-shaped clamping piece 6 and the disc-shaped clamping piece 3 are respectively arranged at two ends of the pipeline 4, the joint of the second arc-shaped clamping piece 6 and the pipeline 4 is solid and seals the pipeline 4, the second arc-shaped clamping piece 6 comprises a top surface arc surface and a bottom surface plane, the top surface arc surface faces outwards, and the joint of the disc-shaped clamping piece 3 and the pipeline 4 is hollow and is communicated with the pipeline 4; the lacrimal duct is implanted into the affected part through the auxiliary pre-device shown in fig. 5; the auxiliary preassembly includes the pre-placement lacrimal tubing 11, the hand-held placement device 12, and the punctum dilation device 13. The top end of a preset lacrimal duct pipe fitting 11 is placed in a pipeline 4 of a lacrimal duct pipe in advance, a hand-held placing device 12 is held by hands, a lacrimal point expanding device 13 is used for probing into the position of a lacrimal point and expanding and dredging, then a second arc-shaped clamping piece 6 at the end part of the pipeline is firstly sent into the lacrimal point, the front end part of the lacrimal duct pipe is slowly placed into the pipeline 4, a disc-shaped clamping piece 3 is kept at the lacrimal point outside the lacrimal duct and is embedded in an eyelid, then the preset lacrimal duct pipe fitting 11 is drawn out, the lacrimal point opening of the second arc-shaped clamping piece 6 is fully closed, so that the lacrimal duct pipe plays a role in blocking lacrimal outflow and supporting, a medicine coating 2 on the pipeline 4 slowly releases medicines and plays a role in resisting bacteria and diminishing inflammation, the lacrimal duct pipe adopts degradable materials, and the medicines which are automatically and completely degraded and disappear after being.

By adopting the lacrimal duct structure shown in fig. 2, the xerophthalmia caused by patients with insufficient tear film water solution, insufficient tear film mucin, insufficient oil and fat accompanied with inflammation and the like is practically solved; the lacrimal duct structure supports the punctum and blocks the discharge of tears, prolongs the stay time of tears in eyes, recovers the micro-ecological environment of eyes, and relieves and cures patients with xerophthalmia; the medicine or biological dressing coating on the medicine coating 2 on the pipeline 4 directly acts on the focus to slowly release the medicine to inhibit inflammatory factors and kill microorganisms (bacteria and demodices), the lacrimal duct tube structure is suitable for primary xerophthalmia patients or secondary xerophthalmia patients (the tear secretion is reduced after excimer surgery and cataract surgery), the lacrimal duct tube structure is automatically degraded after weeks, the pain of the patients is avoided once, the cost and the cost are greatly reduced, and the curative effect is obvious.

Example 3:

as shown in fig. 3, a lacrimal duct tube comprises a first arc-shaped clamping piece 1, a drug coating 2, a duct 4 and a through hole 5, wherein the first arc-shaped clamping piece 1 is arranged at one end of the duct 4, the other end of the duct 4 is connected with one end of an auxiliary guide wire 18, the other end of the auxiliary guide wire 18 is provided with an auxiliary olive-shaped part 19, the joint of the first arc-shaped clamping piece 1 and the duct 4 is hollow and communicated with the duct 4, the first arc-shaped clamping piece 1 comprises a top surface arc surface and a bottom surface plane, the top surface arc surface faces outwards, and the duct 4 comprises a plurality of coaxially connected tube bodies with different inner diameters and/or outer diameters; the lacrimal duct is implanted into the affected part through the auxiliary forceps shown in fig. 6, the auxiliary lacrimal duct traction hook shown in fig. 7, and the auxiliary hollow probe shown in fig. 8.

The auxiliary forceps comprise a holding and clamping point part 26 and a holding part 27. The auxiliary lacrimal passage traction hook comprises a straight rod handle 28 and a traction hook 29. The auxiliary hollow probe comprises a probe handle 30 and a hollow tube needle 31. The auxiliary olive-shaped part 19 of the auxiliary guide wire member 18 is inserted from the upper end of the probe handle 30 to guide the auxiliary guide wire member 18 into the auxiliary hollow probe, the lower port of the hollow tube needle 31 is inserted into the lacrimal punctum, and the lacrimal canaliculus, the common lacrimal duct and the lacrimal sac are guided to the nasolacrimal duct continuously, and the holding and clipping tip part 26 of the auxiliary forceps is used for clipping the pipeline 4 and slowly guiding the pipeline to the hollow tube needle 31; a straight rod handle 28 of the auxiliary lacrimal passage traction hook is held by hand, the auxiliary olive-shaped part 19 coming out of the nasal cavity is hooked by the traction hook 29, the auxiliary olive-shaped part is slowly pulled until the first arc-shaped clamping piece 1 is attached to the lacrimal point and fixed, when the auxiliary guide wire piece 18 comes out of the nasal cavity, the auxiliary hollow probe slowly retreats (namely, the original advancing direction is reversely pulled and pushed), and the inner diameter of the auxiliary hollow probe is larger than the maximum outer diameter of the lacrimal passage pipe, namely, the size of the first arc-shaped clamping piece 1; or the inner diameter of the auxiliary hollow probe is smaller than the maximum outer diameter of the lacrimal duct, namely smaller than the size of the first arc-shaped clamping piece 1, after the lacrimal point is found by the auxiliary hollow probe, the auxiliary hollow probe is taken out, and the auxiliary guide wire piece 18 is continuously guided to the nasolacrimal duct from the lacrimal point through the lacrimal canaliculus, the common lacrimal duct and the lacrimal sac by the auxiliary forceps; then the redundant part of the canal 4 from the nasal cavity is cut off from the upper end of the auxiliary guide wire member 18 according to the actual need, so that the lacrimal duct tube is arranged in the lacrimal duct system, the lacrimal punctum (also called as the lacrimal punctum) is closed, the lacrimal punctum turns outwards, the lacrimal canaliculus is stenosed and blocked, the whole lacrimal duct system is broken, and the like, the lacrimal fluid flows into the canal 4 from the through hole 5 on the canal 4 to play the role of smooth excretion, and meanwhile, the drug is slowly released through the drug coating 2 on the canal 4 with inflammation infection to play the role of antibiosis and antiphlogosis, the lacrimal duct tube adopts degradable material, and the lacrimal duct tube is automatically and completely degraded and disappears after being arranged in the whole lacrimal duct system for a period of time without being taken out again.

By using the lacrimal duct structure shown in fig. 3, the problems of the entire lacrimal duct system of the patient are solved: the lacrimal punctum is blocked and collapsed, the lacrimal punctum is everted, the lacrimal canaliculitis, the lacrimal canaliculus is broken, the lacrimal canaliculus is narrow and blocked, the chronic dacryocystitis, the nasolacrimal duct is blocked, the lacrimal duct has the functions of expanding and supporting and smoothing lacrimal drainage in the whole lacrimal duct system, the medicament or the anti-inflammatory biological dressing in the medicament coating 2 on the duct 4 is slowly released along with inflammatory infection, the function of resisting bacteria and diminishing inflammation is achieved, the lacrimal duct structure is automatically and completely degraded and disappeared after being left in the whole lacrimal duct system for a period of time without taking out, the cure rate is obviously improved, the traditional non-degradable lacrimal duct can not solve the whole lacrimal duct system, only can solve partial lacrimal duct diseases in a limited way and is easy to be blocked, and the duct is easy to break and has a plurality of complications: easy granulation hyperplasia, scar furuncle, inflammatory reaction, inconvenient operation, large difficulty in taking the tube, easy falling off of the tube, difficult recovery and easy repetition, and narrow range of indications.

Example 4:

as shown in fig. 4, a lacrimal duct tube comprises a third arc-shaped clamping piece 7, a drug coating 2, a duct 4 and a through hole 5, wherein the third arc-shaped clamping piece 7 is arranged at the middle upper part of the duct 4, the joint of the third arc-shaped clamping piece 7 and the duct 4 is hollow and is communicated with the duct 4, the third arc-shaped clamping piece 7 comprises a top surface arc surface and a bottom surface arc surface, the radius of the top surface arc surface is smaller than that of the bottom surface arc surface, the top surface arc surface faces outwards, an auxiliary guide wire piece 21 penetrates through the duct 4, and the auxiliary guide wire piece 21 prevents the duct 4 from sliding off the auxiliary guide wire piece 21 in a mode of knotting or penetrating a plugging piece at the; the lacrimal duct is implanted into the affected part through the auxiliary forceps shown in fig. 6 and the auxiliary hollow probe shown in fig. 8. The auxiliary hollow probe probes the opening end of the nasolacrimal duct from the lower end of the nasal cavity, the auxiliary forceps hold the tip clamping part 26 to clamp the pipeline 4 and feed the pipeline into the nasolacrimal duct from the opening of the lower end of the nasolacrimal duct, the auxiliary guide wire 21 is pulled from the upper end and slowly pulled to the third arc-shaped clamping part 7 to fall into the lacrimal sac, the third arc-shaped clamping part 7 plays a role in preventing slipping and falling, and the pipeline 4 is placed at the nasolacrimal duct; the cavity structure of lacrimal duct pipe plays the drainage excretion function to nasolacrimal duct pipe blockage and scope DCR lacrimal sac postoperative and tears from pipeline 4 circumference ascending through-hole 5 and pipeline hole to tears, prevent the adhesion, the while postoperative is accompanied with inflammation infection and is passed through the medicine coating 2 on the pipeline 4 and slowly releases the medicine, play antibiotic anti-inflammatory's function, lacrimal duct pipe adopts degradable material, it disappears to stay to degrade automatically completely after nasolacrimal duct pipe a period, need not to take out again.

By adopting the lacrimal duct structure shown in fig. 4, the problems of chronic dacryocystitis of patients, nasolacrimal duct obstruction and lacrimal anastomosis of nasal cavities, such as expanding and supporting function and lacrimal drainage function, adhesion prevention and postoperative inflammation infection prevention are solved, the medicine is slowly released through the therapeutic medicine coating or the anti-inflammatory biological dressing in the medicine coating 2 on the duct 4, such that the functions of antibiosis and antiphlogosis are achieved, the lacrimal duct structure is completely and automatically degraded after being left in the nasolacrimal duct for a period of time, no taking-out is required, and the cure rate is significantly improved; the traditional non-degradable lacrimal duct can only solve partial obstruction of lacrimal duct in a limited way, and the duct is easy to break and has a plurality of complications: easy granulation hyperplasia, scar furuncle and inflammatory reaction, inconvenient operation, large difficulty in taking the tube, easy reocclusion, unobvious curative effect, easy repetition and narrow application range.

The utility model can provide a plurality of lacrimal ducts with different specifications and models, solves different lacrimal duct diseases almost covering the whole lacrimal duct system and xerophthalmia diseases adapting to the product, has wide application range, and solves the technical defects and limitations of the prior products; although the lacrimal passage system is a small disease, the lacrimal passage system does bring long-term pain to patients, reduces the quality of life and increases the cost of medical treatment, and the diseases are generally from the most common people at the basic level and seriously affect the labor and the quality of life of the patients; because the small diseases are not paid enough attention, revolutionary technical innovation does not exist for many years; the novel idea of the chairman is responded, the life quality and the happiness of people are improved, and the novel chairman is the original motive power of the innovation of the people.

The degradable material comprises a degradable polymer, the degradable polymer is a biodegradable high molecular material, and the degradable polymer comprises any one of more than one of the following materials:

polydioxanone (PPDO), poly (lactic-co-glycolic acid) (PLGA), poly (lactide-co-glycolide), polyglycolic acid (PGA) (also known as polyglycolic acid, polyglycolic acid), racemic polylactic acid (PDLLA), and L-polylactic acid (PLLA);

degradable polyurethanes, degradable polyesters, poly (L-lactide-co-D-lactide), poly (L-lactide-co-D, L-lactide), poly (D-lactide-co-D, L-lactide), poly (lactide-co-glycolide), poly (lactide-co-caprolactone), poly (glycolide-co-caprolactone), poly (lactide-co-dioxanone), poly (glycolide-co-dioxanone), poly (lactide-co-trimethylene carbonate), poly (glycolide-co-trimethylene carbonate), poly (lactide-co-ethylene carbonate), poly (glycolide-co-ethylene carbonate), Poly (lactide-co-propylene carbonate), poly (glycolide-co-propylene carbonate), poly (lactide-co-2-methyl-2-carboxy-propylene carbonate), poly (glycolide-co-2-methyl-2-carboxy-propylene carbonate), poly (3-hydroxybutyrate-co-4-hydroxybutyrate), poly (hydroxybutyrate-co-hydroxyvalerate), poly (3-hydroxybutyrate-co-3-hydroxyvalerate), poly (4-hydroxybutyrate-co-3-hydroxyvalerate), poly (-caprolactone-co-fumarate), poly (-caprolactone-co-propylene fumarate), Poly (lactide-co-ethylene glycol), poly (glycolide-co-ethylene glycol), poly (-caprolactone-co-ethylene glycol), poly (DETOSU-1, 6-HD-co-DETOSU-t-CDM), poly (lactide-co-glycolide-co-caprolactone), poly (lactide-co-glycolide-co-trimethylene carbonate), poly (lactide-co-caprolactone-co-trimethylene carbonate), poly (glycolide-co-caprolactone-co-trimethylene carbonate), and poly (3-hydroxybutyrate-co-3-hydroxyvalerate-co-4-hydroxybutyrate), wherein the lactides include L-lactide, poly (lactide-co-caprolactone), poly (lactide-co-trimethylene carbonate), and poly (3-hydroxybutyrate-co-3-hydroxyvalerate-co-4-hydroxybutyrate) D-lactide and D, L-lactide;

PVP, PVA, starch, biomolecules (such as fibrin, fibrinogen, cellulose, collagen and hyaluronic acid), polyurethane, rayon triacetate, cellulose, acetic acid, cellulose butyrate, cellulose acetate butyrate, cellophane, nitrocellulose, cellulose propionate, cellulose, and carboxymethyl cellulose.

In particular, the biodegradable polymer material is a polymer material blended or copolymerized by PLA and PLGA (or PLC, PCL), and even can be a blend of two or more copolymers. On one hand, the polymer has been widely applied to three types of medical device products such as vascular stents, sutures, orthopedic implants and the like for years, has better biocompatibility, and avoids complications caused by materials. In addition, according to clinical practical conditions, the proportion of the materials is set so as to achieve good collocation of slow release and degradation period. Wherein, the mass percentage of PLA in the polymer material blended or copolymerized by PGA and PLA can be 0-85%, preferably 5-50%; the PCL can be 0-50% by mass, preferably 5-30% by mass of the PLA and PCL blended polymer material. More recently, they may be a blend of two copolymers, for example: 1090PLGA and 8515PLGA are blended, 1090PLGA and 9010PLGA are blended, 8515PLGA and 5050PLGA are blended, 1090PLGA and 7030PLC are blended, and the like, so that the method can be used for producing particles with different degradation time, meet the requirements of different degradation time, and can meet the requirements through the adjustment of copolymerization ratio or the adjustment of blending ratio.

Preferably, the molecular weight of the degradable polymer is 5000-; more preferably 12000-18000; the higher the molecular weight, the longer the degradation period, and the degradation period of about 3 months is preferably satisfied. Preferably, when the particle size of the particles is in the first normal distribution, the molecular weight is preferably selected from 5000-; when the particle size of the particles is in the second normal distribution, 10000-; when the particle size of the particles is in the first normal distribution, the molecular weight is preferably 20000-. Blendable polymers include synthetic and natural hydrolytically degradable polymers in addition to the degradable polymers described above. Synthesizing the hydrolytically biodegradable polymer may include hydrolytically degrading polyesters including poly (L-lactic-glycolic acid) (PLGA). Typical naturally biodegradable polymers include chitosan. Typical water-soluble polymers include poly (ethylene glycol) (PEG), PEG block polymers, PEG/PLA and PEG polymers, PEG random or alternating copolymers, such as polyethylene glycol/PLGA copolymers, sucrose, starch, algin, polyvinylpyrrolidone (PVP), and poly (vinyl alcohol) (PVA). Poly (N-acetylglucosamine) (chitin), poly (ester), poly (3-hydroxybutyrate), poly (4-hydroxybutyrate), poly (hydroxybutyrate-hydroxyvalerate), poly (DL-lactide-co-caprolactone), poly (glycolide-co-caprolactone), poly (trimethylene carbonate), polyesteramide, poly (glycolic acid-trimethylene carbonate), poly (ether-ester) (e.g., PEO/polylactic acid), polyphosphazene, and the like. The drug-containing sustained-release microparticles described above can be prepared by several methods: such as, but not limited to, mixing method, melting method, dissolving method, spray drying method for preparing particles, dissolving method combined with freezing (drying) pulverization method, liposome coating method and emulsification method, etc., wherein the dissolving method (i.e. solvent evaporation method), freezing (drying) pulverization method, drying method, spray drying method and emulsification method are preferred, after mixing particles with various solvents, various sustained release injections can be prepared, the particle size of the sustained release particles is determined by specific needs, but not limited to, 5-200 μm, but is preferably 50-150 μm, the drug or sustained release particles can be prepared into microspheres, submicrospheres, microemulsions, nanospheres, particles or spherical pellets, the shape of the particles can be round, oval, polygonal, with convex thorns, with hooks, with sharp corners, etc., and can be determined according to actual conditions and manufacturing methods.

The drug coating comprises drug-containing slow release particles, the drug-containing slow release particles can be prepared into injection with fixed solvent, and the solvent can be distilled water, water for injection, physiological flushing liquid, absolute ethyl alcohol or buffer solution prepared from various salts. Or microparticle and special solvent containing suspending agent, wherein the suspending agent is selected from sodium carboxymethyl cellulose, (radix Rubi Corchorifolii Immaturus) glycerol, simethicone, glycerol, carbomer, mannitol, sorbitol, surfactant, Tween 20, Tween 40 and Tween 80 or their combination. The drug-containing slow-release particles for the lacrimal passage mucosa can directly act on the pathological change part of the lacrimal passage, specifically, the drug and the degradable polymer are mixed to prepare particles with different sizes, and the release time of the drug is controlled by controlling the size and the distribution of the particle size of the particles. In clinic, doctors can select particles with different release times to prepare injection, the injection is directly injected at the position of pathological changes on the lacrimal passage system mucous membrane, the pathological lacrimal passage mucous membrane can be directly discovered through an endoscope, and the mucous membrane becomes whitish or pustule or granulation; is easy to find and inject clinically. The medicine can be released for a long time after injection, and has a continuous therapeutic effect. After the lesion part is treated, the color of the mucous membrane is recovered to be normal, and the cavity channel of the lacrimal passage system is recovered to be normal.

The drug coating comprises any one or more of the following: anti-inflammatory agents, antibacterial agents, antifungal agents, antiviral agents, chemotherapy agents, and antitumor agents.

1. Anti-inflammatory agents

Comprises the following medicaments for promoting epithelization, adhesion prevention and hemostasis: carboxymethyl chitosan/chitosan sushi/sodium hyaluronate/esterified hyaluronic acid/carboxymethyl chitosan/aqueous solution containing 0.01% of hypochlorous acid and 0.9% of sodium chloride/acellular biological amniotic membrane/active silver ion antibacterial solution/nano silver particles) alpha-n-butyl cyanoacrylate/alpha-n-octyl cyanoacrylate/physiological seawater).

Steroidal anti-inflammatory drugs include: 21-acetoxypregnenolone, alclometasone, progesterone, amcinolone acetonide, beclomethasone, betamethasone, budesonide, prednisolone, clobetasol, clobetasone, clocortolone, prednisolone, corticosterone, cortisone, cortazole, deflazacort, desonide, desoximetasone, dexamethasone, diflorasone, diflucortolone, difluoropregnane butyl ester, glycyrrhetinic acid, fluzacort, fluocinolone acetonide, flumethasone, fossilsone, fluocinonide, fucortolone, fluorometholone, fluoromethalone, flunomide, flupredlone acetate, fluprednide, fluroxypyr, fluticasone propionate, aldehydione, halcinonide, halobetasol propionate, halomethasone, haloprednisolone, hydrocortisone, lotone, mepartone, methylprednisolone, medrysone, Methylprednisolone, mometasone furoate, paramethasone, prednisone ester, prednisolone, 25-diethylamino acetate prednisolone, prednisolone sodium phosphate, prednisone, prednisolone valerate, prednisolone, rimexolone, tixocortol, triamcinolone acetonide, triamcinolone hexacetonide, and derivatives and combinations thereof.

Non-steroidal anti-inflammatory agents include: cyclooxygenase (cox) inhibitors. Such Cyclooxygenase (COX) inhibitors may include COX-1 or COX non-specific inhibitors, e.g., salicylic acid derivatives, aspirin, sodium salicylate, choline magnesium trisalicylate, salsalate, diflunisal, sulfasalazine, olsalazine; para-aminophenol derivatives, for example, acetaminophen; indole and indene acetic acids, e.g., indomethacin and sulindac; isoarylacetic acids, for example, toluoylpicolinic acid, diclofenac, ketorolac; arylpropionic acids, for example, ibuprofen, naproxen, flurbiprofen, ketoprofen, fenoprofen, oxaprozin; anthranilic acids (fenamic acid), e.g., mefenamic acid, meloxicam; enolic acids, such as, for example, oxicams (piroxicam, meloxicam); aldones, for example, nabumetone. COX inhibitors may also include the alternative cyclooxygenase enzyme COX2, e.g., diaryl substituted furanones, rofecoxib; diaryl substituted pyrazoles, celecoxib; indoleacetic acids, such as etodolac; sulfonamides, such as nimesulide.

2. Antibacterial agent

The antibacterial agent includes: nano silver particles, aminoglycosides, amide alcohols, ansamycins, beta-lactam antibiotics, such as penicillins, lincomycins, macrolides, nitrofurans, quinolones, sulfonamides, sulfones, tetracyclines, vancomycin, and derivatives and combinations thereof. Penicillin class agents that may be used in the stents of the present application include, but are not limited to: amicillin, oxacillin diester, amoxicillin, ampicillin, aspoxicillin, azicillin, amoxicillin, benzylpenicillic acid, penicillin sodium, carbenicillin, cairinin, cloxacillin, ciclacillin, dicloxacillin, epicillin, fenbenicillin, flucloxacillin, hexacillin, lenacilin, maytansillin, methicillin sodium, mezlocillin, nafcillin sodium, oxacillin, pencillin hydroiodide, benzathine, penicillin G, benzhydrylamine, penicillin G calcium, hydrabamine G, penicillin G potassium, procaine G, penicillin N, O, penicillin V, benzathine penicillin V, hydrabamine V, penicillin G, piperacillin potassium, piperacillin, pivampicillin, pimicin, propicillin, penicillin, Quinacilin, sulbenicillin, sultamicillin, phthalampicillin, temocillin, ticarcillin.

3. Antifungal agent

Antifungal agents include: allylamines, imidazoles, polyenes, sulfurized carbamates, triazoles, and derivatives thereof. Antiparasitic agents include, but are not limited to, atovaquone, clindamycin, dapsone, bisquinoline, metronidazole, pentamidine, primaquine, pyrimethamine, sulfadiazine, trimethoprim/sulfamethoxazole, trimetrexate, and mixtures thereof.

4. Antiviral agent

Antiviral agents include: acyclovir, famciclovir, edexuridine, ganciclovir, foscarnet, cidofovir, fomivirsen, HPMPA (9- (3-hydroxy-2-phosphomethoxypropyl) -adenine), PMEA (9- (2-phosphomethoxypropyl) -adenine), HPMPG (9- (3-hydroxy-2-phosphomethoxypropyl) -guanine), PMEG (9- [ 2-phosphomethoxypropyl ] guanine), HPMPC (1- (2-phosphomethoxy-3-hydroxypropyl) -cytosine), ribavirin, EICAR (5-ethynyl-1-beta-D-ribofuranosyl-1H-imidazole-4-carboxamide), pyrazolofuranidin (3- [ beta-D-ribofuranose ] -4-hydroxypyrazole -5-carboxamide), 3-diclazuline, GR-92938X (1- β -D-ribofuranosyl-1H-pyrazole-3, 4-dicarboxamide), LY253963(1,3, 4-thiadiazol-2-yl-cyanamide), RD3-0028(1, 4-dihydro-2, 3-benzyldisulfide), CL387626(4 '-bis [4,6-D ] [ 3-aminobenzene-N, N-bis (2-carbamoylethyl) -sulfonimide ] -1,3, 5-triazin-2-ylamino-biphenyl-2-, 2' -disulfonic acid sodium salt), BABIM (bis [ 5-amidino-2-benzimidazol-l ] -methane) NIH351, 351, And mixtures thereof.

5. Chemotherapeutic and antineoplastic agents

Chemotherapeutic and antineoplastic agents include: anti-cancer agents (e.g., tumor chemotherapeutics, modulators of biological effects, angiogenesis inhibitors, hormone receptor blockers, hyperthermic agents, and other agents that can destroy or inhibit tumorigenesis and growth), for example, alkylating agents or other agents that can kill cancer cells directly by DNA attack (e.g., cyclophosphamide, isocyclophosphatamine), nitrosoureas or other agents that kill cancer cells by inhibiting cellular DNA repair (e.g., carmustine (BCNU), lomustine (CCNU)), antimetabolites or other agents that prevent cancer cell growth by interfering with specific cellular functions, typically DNA synthesis (e.g., 6-thiopurine, 5-fluorodioxopyridine (5FU), antitumor antibiotics, and other compounds that can bind or set DNA and prevent DNA synthesis at one time (e.g., doxorubicin, daunomycin, epirubicin, idarubicin, etc.) (e.g., doxorubicin, daunorubicin, etc.), mitomycin-C, bleomycin), plant (vinca) alkaloids and other plant-derived anti-tumor agents (e.g., vincristine, vinblastine), steroid hormones, hormone inhibitors, hormone receptor antagonists and other agents that affect growth of hormone responsive cancers (e.g., tamoxifen, herceptin, aromatase inhibitors, e.g., aminoisostearic and formestane, triazole inhibitors, e.g., letrozole and anastrozole, steroid inhibitors, e.g., exemestane), angiostatic proteins, small molecules, gene therapy and/or other agents that inhibit tumor angiogenesis or vascularization (e.g., meth-1, meth-2, thalidomide), bevacizumab (avastin), sharksamide, endostatin, Angiozyme, 941-941 (cancerocide), CC-5013(Revimid, a thalidomide derivative), medi-522(Vitaxin), 2-methoxyestradiol (2ME2, Panzem), Carboxyamidotriazole (CAI), combretastatin a4 prodrug (CA4P), SU6668, SU11248, BMS-275291, COL-3, EMD121974, IMC-1C11, IM862, TNP-470, celecoxib (celecoxib), rofecoxib (vicox), interferon alpha, interleukin 12(IL-12), or any of the compounds identified at science vol.289, pp.1197-1201 (aug.17,2000), which are all incorporated herein by reference. Biological effect modulating agents (e.g., interferons, bacillus calmette-guerin (BCG), monoclonal antibodies, interleukin 2, Granulocyte Colony Stimulating Factor (GCSF), etc.), PGDF receptor antagonists, herceptin, asparaginase, busulfan, carboplatin, cisplatin, carmustine, chlorambucil, cytarabine, dacarbazine, etoposide, flucarbazide, gemcitabine, hydroxyurea, ifosfamide, irinotecan, lomustine, melphalan, mercaptopurine, methotrexate, thioguanine, thiotepa, raltitrexed, topotecan, tritosulfate, vinblastine, vincristine, mitoazotron, oxaliplatin, procarbazine, streptococcin, paclitaxel, docetaxel, azathioprine derivatives homologs, derivatives of these compounds, and compositions thereof.

The foregoing description of the specific embodiments of the invention has been presented. It is to be understood that the present invention is not limited to the specific embodiments described above, and that various changes or modifications may be made by those skilled in the art within the scope of the appended claims without departing from the spirit of the invention. The embodiments and features of the embodiments of the present application may be combined with each other arbitrarily without conflict.

Claims (10)

1. The utility model provides a degradable lacrimal passage pipe, its characterized in that, includes pipeline, the fastener and the medicine coating that degradable material made, the pipeline is provided with one or more through-holes in the week, the fastener is cambered surface shape and/or disc, and the coaxial setting of one or more fastener is at tip or the middle part of pipeline, and the size of fastener is greater than the size of pipeline, coats the medicine coating on the internal surface and/or the surface of pipeline.

2. The degradable lacrimal canal of claim 1, wherein the connection between the clip and the canal is hollow and in communication with the canal.

3. The degradable lacrimal canal of claim 1, wherein the junction of the clip and the canal is solid and seals off the canal.

4. The degradable lacrimal duct of claim 1, wherein the cambered fastener comprises a top surface cambered surface and a bottom surface, the top surface cambered surface is connected with the bottom surface, and the bottom surface is a plane or a cambered surface with a radius larger than that of the top surface cambered surface.

5. The degradable lacrimal duct tube of claim 1, wherein the tube is a flexible tube capable of bending.

6. The degradable lacrimal duct tube of claim 1, wherein the tube comprises a plurality of coaxially connected tubes of different inner and/or outer diameters.

7. The degradable lacrimal duct tube of claim 1, wherein an inner diameter and/or an outer diameter of the duct remains constant in a duct extending direction.

8. The degradable lacrimal duct tube of claim 1, wherein the tube is integrally formed with a clip.

9. The degradable lacrimal canal of claim 1, wherein the through holes on the circumference of the canal are staggered, and the diameter of the through holes is smaller than the outer diameter of the canal.

10. A degradable lacrimal passage tube is characterized by comprising a tube made of degradable materials, clamping pieces made of degradable materials and a medicine coating, wherein one or more through holes are formed in the circumferential direction of the tube, the clamping pieces are arc-shaped and/or disc-shaped, the one or more clamping pieces are coaxially arranged at the end or the middle of the tube, the size of the clamping pieces is larger than that of the tube, and the medicine coating is coated on the inner surface and/or the outer surface of the tube;

the connecting part of the clamping piece and the pipeline is hollow and is communicated with the pipeline;

the joint of the clamping piece and the pipeline is solid and plugs the pipeline;

the cambered surface-shaped clamping piece comprises a top surface cambered surface and a bottom surface, the top surface cambered surface is connected with the bottom surface, and the bottom surface is a plane or a cambered surface of which the radius is larger than that of the top surface cambered surface;

the pipeline is a flexible pipeline capable of being bent;

the pipeline comprises a plurality of sections of coaxially connected pipe bodies with different inner diameters and/or outer diameters;

the inner diameter and/or the outer diameter of the pipeline are/is kept unchanged in the extending direction of the pipeline;

the pipeline and the clamping piece are integrally formed;

the through holes in the circumferential direction of the pipeline are distributed in a staggered mode, and the diameter of each through hole is smaller than the outer diameter of the pipeline.

Images